Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation

1 Jan 1997

Abstract excerpt

BACKGROUND: Orthotopic liver transplantation for end-stage hepatitis-B-virus (HBV) infection is commonly complicated by recurrence of HBV. Lamivudine, a cytosine nucleoside analogue, has been shown to suppress HBV infection. We report the development of resistance to lamivudine in three patients who underwent transplantation for end-stage liver disease secondary to hepatitis B. METHODS: Two of the patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hepatitis B Virus Studies
Share to Hepatitis C virus research
Share to HIV/AIDS drug development and treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 8988118
DOI: 10.1016/s0140-6736(96)02266-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantationPMID 8988118Read ↗

Prophylaxis of hepatitis B recurrence in post-liver transplantation patients with lamivudine-resistant YMDD mutant.Semantic proximity Read ↗

The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss.Semantic proximity Read ↗

Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants.Semantic proximity Read ↗

Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin.Semantic proximity Read ↗

No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants.Semantic proximity Read ↗

Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: a meta-analysis.Semantic proximity Read ↗

[Post-transplant prophylaxis of the recurrence of lamivudine-resistant YMDD mutant hepatitis B virus in liver recipients].Semantic proximity Read ↗

Recurrent hepatitis C following liver transplant: diagnosis, natural history, and therapeutic options.Semantic proximity Read ↗

High viremia, prolonged Lamivudine therapy and recurrent hepatocellular carcinoma predict posttransplant hepatitis B recurrence.Semantic proximity Read ↗

Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation.Semantic proximity Read ↗

Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term prophylaxis of hepatitis B recurrence after liver transplantation.Semantic proximity Read ↗

Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.